Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer

被引：0
|
作者：
Francesconi, A.
Kotasek, D.
Burge, M.
Smith, G.
Lickliter, J.
机构：
[1] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[2] Adelaide Canc Ctr, Adelaide, SA, Australia
[3] Cytopia Res Pty Ltd, Melbourne, Vic, Australia
[4] Frankston Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer.
    Takimoto, CH
    Verschraegen, C
    Young, D
    Oldham, FB
    Bernareggi, A
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9118S - 9118S
  • [32] Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer.
    Takimoto, CH
    Schwartz, G
    Romero, O
    Patnaik, A
    Tolcher, A
    Garrison, M
    Oldham, FB
    Bernareggi, A
    Rowinsky, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 145S - 145S
  • [33] Phase I study of PM00104, a novel cytotoxic anti-cancer drug, administered to patients with advanced solid tumors or lymphoma
    Gallerani, E.
    Yap, T. A.
    Lopez, A.
    Coronado, C.
    Shaw, H.
    Florez, A.
    Heras, B. de las
    Cortes-Funes, H.
    de Bono, J.
    Paz-Ares, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse.
    Rischin, Danny
    Beale, Philip James
    Rossi, Emma Caroline
    Goh, Jeffrey C.
    Vaughan, Michelle Margaret
    Tenney, Meaghan Elizabeth
    Martyn, Julie
    Sommeijer, Dirkje Willemien
    Iglesias, Jose Luis
    Kremmidiotis, Gabriel
    Simpson, Jeremy Andrew
    Doolin, Elizabeth E.
    Lavranos, Tina C.
    Leske, Annabell F.
    Veitllard, Anne-Sophie
    Stockier, Martin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
    Rischin, Danny
    Bibby, David C.
    Chong, Geoff
    Kremmidiotis, Gabriel
    Leske, Annabell F.
    Matthews, Clayton A.
    Wong, Shirley S.
    Rosen, Mark A.
    Desai, Jayesh
    CLINICAL CANCER RESEARCH, 2011, 17 (15) : 5152 - 5160
  • [36] A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer.
    Calvo, E
    Rowinsky, EK
    Tolcher, AW
    Chu, QS
    Beeram, M
    Forero, L
    Mettinger, KL
    Eastham, E
    Goetz, AD
    Patnaik, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [37] A phase I study of a novel taxane, TL310, orally administered every week in patients (pts) with advanced solid tumors
    Glasspool, R. M.
    Boddy, A. V.
    Evans, T. R.
    Griffin, M. J.
    Anthoney, A.
    Barker, A.
    Longley, R. E.
    Twelves, C. J.
    Edwards, C. J.
    Wilcox, H. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors.
    Ricart, A. D.
    Cooney, M.
    Sarantopoulos, J.
    Brell, J.
    Locke, K. W.
    Gammans, R. E.
    Medina, G.
    Zambito, A.
    Tolcher, A. W.
    Remick, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [39] A phase I study of SRA737 (formerly known as CCT245737) administered orally in patients with advanced cancer.
    Chenard-Poirier, Maxime
    Garces, Alvaro Henrique Ingles
    Jones, Robert Hugh
    Quinton, Amy
    Plummer, Elizabeth R.
    Drew, Yvette
    Kowalski, Mark Marion
    Klencke, Barbara J.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
    Tresca, P.
    Tosi, D.
    van Doorn, L.
    Fontaine, H.
    Gaast, A. V.
    Veyrat-Follet, C.
    Oprea, C.
    Dieras, V.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345